All posts by: admin

MicroLyte® Ag Matrix Clinical Performance to be Featured at National Wound Healing Conference

Madison, WI, April 22, 2019– Imbed Biosciences, a developer of advanced biomaterials and soft tissue repair devices, announced today that clinical results documenting the use of its flagship product, MicroLyte® Ag resorbable antimicrobial wound matrix, will be presented at the Spring Symposium on Advanced Wound Care (SAWC) in San Antonio, TX from May 8-10, 2019.  The company will also have a presence in the exhibitor space at booth #133.  SAWC is the nation’s largest interdisciplinary wound care forum.

The poster presentations, delivered by several of Imbed’s clinical collaborators, will highlight results in a variety of complex, chronic wounds and surgical applications.  The clinical case series were conducted independently at the Institute for Advanced Wound Care (Montgomery, AL), East Tennessee State University (Johnson City, TN), and Premier Surgical New Jersey (Brick Township, NJ) and typically evaluated wound closure after application of MicroLyte® Ag Matrix to leg ulcers, surgical wounds in diabetic patients, and various chronic colonized wounds. 

“The latest round of work that our clinical collaborators will share at SAWC continues to exemplify the tremendous wound healing capacity that MicroLyte® Ag Matrix possesses.  The clinical outcomes associated with the use of MicroLyte® Ag Matrix have the profound ability to change people lives,” said Ankit Agarwal, President and CEO of Imbed Biosciences. “We are excited to continue to work with these collaborators and others with the goal of assisting in healing many types of acute, chronic, and surgical wounds.” 

Dr. Ryan Chatelain will prominently feature MicroLyte® Ag Matrix in a podium presentation on May 9 at 2:55pm entitled “The Efficacy of a Synthetic Bioresorbable Synthetic Antimicrobial Matrix as an Implantable Material for At-Risk Surgical Wounds”.

Additional SAWC poster presentations of interest during the SAWC Poster Gala from 7:15 to 8:45pm on May 9 will include:

The Use of an Absorbable Polyvinyl/Polymeric Microfilm Matrix with Silver in the Treatment of Venous Ulcers: A Pilot Study

Terry Treadwell, MD; Donna Walker, LPN; Maggie Taylor, NA; Angela Pickens, RN; Jessica Baker, RN

Institute for Advanced Wound Care, Montgomery, AL

Use of an absorbable polyvinyl alcohol polymeric microfilm matrix loaded with silver helps to reliably heal chronic colonized wounds

Dr. Jarrod Kaufman, MD

Premier Surgical New Jersey (Brick Township, NJ)

Dr. Chatelain will also present his clinical findings during the SAWC Poster Gala on the evening of May 9.

Additionally, SAWC Exhibit Hall visitors will get an up-close look at Imbed’s groundbreaking, FDA-cleared MicroLyte® Ag Matrix, a fully-resorbable antimicrobial wound matrix.   MicroLyte® Ag Matrix is primarily composed of an ultrathin, resorbable polymeric film, which means it never needs to be removed from the wound bed.  MicroLyte® Ag Matrix is also fully synthetic, so there is no risk of disease transmission from animal based-components and it has a long shelf-life under ambient conditions (2 years or more).  MicroLyte® Ag Matrix is cleared for application in acute wounds such as lacerations, skin tears, abrasions, surgical wounds (e.g., donor and graft sites, incisions), partial thickness first- and second-degree burns, and partial to full-thickness dermal ulcers such as, diabetic, decubitus, venous stasis, arterial stasis ulcers.  The product may be applied daily or up to every 3 days, depending on the wound and the healing progression. The duration of the treatment depends on wound type and healing conditions.

About Imbed Biosciences, Inc.

Imbed Biosciences is a privately held medical device company developing next-generation medical devices for the management of burns, chronic ulcers, gastro-intestinal defects, and soft-tissue repair. The company has a portfolio of products in development based on its patented MicroLyte® matrix polymeric multilayer platform that presents bioactive molecules on tissue surfaces to combat local pain and infections, support soft-tissue repair, and reduce antibiotic/opioid abuse. Imbed is backed by venture capital group WISC Partners based in Madison, WI, and has received research grants from the National Institutes of Health and the National Science Foundation. For more information, please visit www.imbedbio.com,www.MicroLyteAg.com,facebook.com/imbedbio, or @MicroLyteAgMtrx on twitter.

Contact information:

Jeff Dalsin, PhD,

Vice President, Products

jdalsin@imbedbio.comPhone: 608-237-1525 ext. 403

Imbed Biosciences Closes $2 Million in Series A Financing to Commercialize Wound Healing Matrix

Madison, Wisconsin (April 18, 2019) – Imbed Biosciences, Inc. (Imbed), a medical device company emerging as a leader in the development of advanced therapies for soft tissue repair, announced today that it has secured $2 million in a Series A Preferred Stock equity financing. The funding will be used to commercialize company’s FDA-cleared MicroLyte® Ag Antimicrobial Matrix indicated for the management of chronic ulcers, burns, and surgical wounds. 

“Thousands of patients with a variety of chronic wounds have already been successfully treated with MicroLyte® Ag Matrix, which is now available on the formulary of several hospital systems and is reimbursed by Medicare Part B. With this new funding, we will be building up our product distribution channels to expand our reach throughout United States,” said Ankit Agarwal, PhD, Imbed’s cofounder and CEO. 

This investment round was organized by Formidable Asset Management (Formidable), a Registered Investment Advisor based in Cincinnati, OH. “We are extremely excited to work with the team at Imbed to help them scale the business and are committed to seeing their surgical matrix technology transform the standard-of-care for hundreds of millions of patients with complex wounds,” said William Brown, owner and CEO of Formidable. 

MicroLyte® Ag Matrix is a next-generation ultrathin wound matrix made with bioresorbable polymers and a patented antimicrobial silver nanotechnology. “The microscale matrix intimately conforms to a wound bed, provides an environment conducive to cell growth, and kills bacteria in contact with the tissue surface. It has provided a strong foundation for tissue regeneration in many complex contaminated wounds that did not respond to months of standard-of-care”, said cofounder Dr. Michael Schurr, MD, Chair of General Surgery at the Mountain Area Health Education Center and trauma surgeon at Mission Health Hospital in Asheville, NC.

In conjunction with the financing, Elizabeth B. Taylor, an investment management professional and experienced COO of investment hedge funds, has joined the company’s Board of Directors, which includes David Guinther, Dr. Michael Schurr and Ankit Agarwal.

“Imbed has earned an inflection point opportunity here as we further bring MicroLyte® Matrix to the market and by doing so advance the science of healing complex wounds,” said David Guinther, General Partner at WISC Partners. 

About Imbed Biosciences 

Imbed Biosciences is registered with FDA as a medical device manufacturer and maintains an ISO 13485 certified quality management system. The company has a portfolio of products in development based on its patented MicroLyte® Matrix technology focused on combating local pain and infections in complex wounds, such as burns, chronic ulcers, surgical wounds, hernia repair, colorectal surgeries, dural repair, orthopedic implants, and cesarean sections. A portion of Imbed’s research funding comes from ongoing Small Business Innovation Research (SBIR) grants from the National Institute of Arthritis, Musculoskeletal, and Skin Diseases (NIAMS). More information at: www.imbedbio.comand www.MicroLyteAg.com.

Contact information:

Ankit Agarwal, PhD, CEO

ankit@imbedbio.comPhone: 608-237-1525 ext. 402

Imbed Biosciences’ Clinical Successes to be Highlighted at SAWC Fall 2018

Madison, WI, July 27, 2018 – Imbed Biosciences, a developer of advanced biomaterials and soft tissue repair devices, announced today that clinical results documenting the use of its flagship product, MicroLyte® Ag Matrix resorbable antimicrobial wound matrix, will be presented at the Fall Symposium on Advanced Wound Care (SAWC) in Las Vegas, NV from November 2-4, 2018.  The company will also have a presence in the exhibitor space at booth #104.  SAWC is the nation’s largest interdisciplinary wound care forum.

The poster presentations, delivered by several of Imbed’s clinical collaborators, will highlight results in a variety of complex, chronic wounds and surgical applications.  The clinical case series were conducted independently at Rush University Medical Center (Chicago, IL), East Tennessee State University (Johnson City, TN), Duke Wound Management Clinic (Durham, NC), and the Institute for Advanced Wound Care (Montgomery, AL), and typically evaluated wound closure after application of MicroLyte® Ag Matrix to diabetic wounds, leg ulcers, an infected surgical site, and a radiation wound.  In one series, MicroLyte® Ag Matrix was also implanted in non-healing diabetic ulcers.

“The work that will be presented at SAWC represents a pivotal point for Imbed.  We are excited to see positive clinical outcomes in the hands of skilled wound healing practitioners.  We believe that these improved clinical outcomes will naturally lead to improved economic outcomes for small independent practices and large healthcare systems, alike” said Ankit Agarwal, President and CEO of Imbed Biosciences. “We are grateful to be working with collaborators who continually push the bounds of what we know MicroLyte® Ag Matrix can do.”

Additionally, prospective users who visit the SAWC exhibit hall will get an up-close look at Imbed’s groundbreaking, FDA-cleared MicroLyte® Ag Matrix resorbable antimicrobial wound matrix.   MicroLyte® Ag Matrix is primarily composed of an ultrathin, resorbable polymeric film, which means it never needs to be removed from the wound bed.  MicroLyte® Ag Matrix is also fully synthetic, so there is no risk of disease transmission from animal based-components and it has a long shelf-life (2 years or more) under ambient conditions.  MicroLyte® Ag Matrix is cleared for application in acute wounds such as lacerations, skin tears, abrasions, surgical wounds (e.g., donor and graft sites, incisions), partial thickness first- and second-degree burns, and partial to full-thickness dermal ulcers such as, diabetic, decubitus, venous stasis, arterial stasis ulcers.  The product may be applied daily or up to every 3 days, depending on the wound and the healing progression. The duration of the treatment depends on wound type and healing conditions.

Poster presentations of interest include:

The Use of an Absorbable Polyvinyl/Polymeric Microfilm Matrix with Silver in the Treatment of Venous Ulcers: A Pilot Study

Terry Treadwell, MD, Donna Walker, LPN, Maggie Taylor, NA, Angela Pickens, RN, Jessica Baker, RN

Institute for Advanced Wound Care, Montgomery, AL

 

The Efficacy of an Ultrathin Bioresorbable Silver Impregnated Polymeric Multilayer Matrix in the Treatment of Chronic Wounds and as an Implantable Material for at Risk Surgical Wounds

Ryan Chatelain, DPM

East Tennessee State University, Johnson City, TN

 

Problematic Leg Ulcers Require Innovative Solutions

Amelia B. Beatty, NP, Penny Jones, NP

Duke Wound Management Clinic, Durham, NC

 

An Ultrathin Bioresorbable Matrix with Antimicrobial Silver in the Treatment of Chronic Contaminated Wounds

Thea P. Price, MD

Rush University Medical Center, Chicago, IL

 

About Imbed Biosciences, Inc.

Imbed Biosciences is a privately held medical device company developing next-generation medical devices for the management of burns, chronic ulcers, gastro-intestinal defects, and soft-tissue repair. The company has a portfolio of products in development based on its patented MicroLyte® matrix polymeric multilayer platform that presents bioactive molecules on tissue surfaces to combat local pain and infections, support soft-tissue repair, and reduce antibiotic/opioid abuse. Imbed is backed by venture capital group WISC Partners based in Madison, WI, and has received research grants from the National Institutes of Health and the National Science Foundation. For more information, please visit www.imbedbio.com, www.MicroLyteAg.com, facebook.com/imbedbio, or @MicroLyteAgMtrx on twitter.

 

Imbed Biosciences Receives ISO 13485:2016 Certification

Madison, WI, July 3, 2018 – Imbed Biosciences, a developer of advanced biomaterials and soft tissue repair devices, announced today that the company has formally received its ISO 13485:2016 certificate.  The new certificate supersedes the existing certification and confirms that the company is compliant with the newest international standard governing the quality manufacture of medical devices.  The transition audit was conducted by British Standards Institution (BSI), a UK standards body and global business certification company.

“This transition to the new version of ISO 13485 is a great accomplishment for our team.  It allows Imbed’s partners and customers to have the highest level of confidence in the quality of our products.  Furthermore, updated ISO certification will help enable us to market our products internationally.  This is a key element of our application for CE marking for MicroLyte® Ag Matrix, which will be submitted later this quarter” said Jeff Dalsin, Vice President of Product Development and Quality.

About Imbed Biosciences, Inc.

Imbed Biosciences is a privately held medical device company developing next-generation medical devices for the management of burns, chronic ulcers, gastro-intestinal defects, and soft-tissue repair. The company has a portfolio of products in development based on its patented MicroLyte® matrix polymeric multilayer platform that presents bioactive molecules on tissue surfaces to combat local pain and infections, support soft-tissue repair, and reduce antibiotic/opioid abuse. Imbed is backed by venture capital group WISC Partners based in Madison, WI, and has received research grants from the National Institutes of Health and the National Science Foundation. For more information, please visit www.imbedbio.com, www.MicroLyteAg.com, facebook.com/imbedbio, or @MicroLyteAgMtrx on twitter.

Imbed Biosciences Launches MicroLyte® Ag Antimicrobial Matrix Clinical Research Program

Madison, WI, June 5, 2018– Imbed Biosciences, a developer of advanced biomaterials for soft tissue repair and regeneration, today announced the launch of a MicroLyte® Ag Antimicrobial Matrix clinical research program which will comprise multiple sites, studies and a nationwide patient registry.

The first study, underway at Mission Health System in Asheville, NC, is an investigation of MicroLyte® Ag Matrix in complex and non-healing wounds.  Mission Health is coordinating and conducting the 100-patient prospective clinical study, which will assess the efficacy of MicroLyte® Ag Matrix when used in complex skin wounds, including venous stasis ulcers, pressure ulcers, and diabetic foot ulcers.  The primary objective of the study is to determine the percentage of change in the wound size when treated with MicroLyte® Ag Matrix. A secondary objective includes evaluating how long wound closure takes when using MicroLyte® Ag Matrix in the wound. Patients treated with MicroLyte® Ag Matrix are being followed for up to 12 weeks.

MicroLyte® Ag Matrix is a class II medical device which has been 510(k) cleared by the US Food and Drug Administration (FDA). It is a fully-synthetic bioresorbable wound matrix composed primarily of a polyvinyl alcohol sheet with a polymeric surface coating containing ionic and metallic silver. MicroLyte® Ag Matrix is intended for use on partial and full thickness wounds including pressure ulcers, venous stasis ulcers, diabetic ulcers, first and second-degree burns, abrasions and lacerations, donor sites and surgical wounds.  MicroLyte® Ag Matrix may also be used over debrided and grafted partial thickness wounds.  MicroLyte® Ag Matrix works differently than conventional silver-impregnated wound dressings and is designed to be safer and more readily adherent to the varied topography of complex wound beds where potential sources of infection can sequester themselves.   MicroLyte® Ag Matrix uniquely combines bioresorbability and antimicrobial effectiveness in a fully-synthetic product—a first of its kind in the wound care space. Components of the matrix have been shown to support cell growth and vascularization to support wound healing.

Chronic non-healing ulcers are a significant medical problem and the incidence of these wounds is expected to increase as the United States population ages and diabetes becomes more prevalent. The three major subcategories include diabetic foot ulcers (DFU), venous stasis ulcers, and pressure ulcers. The major challenge in the management of open wounds is the reduction of infection causing bacteria. Standard therapies only cure approximately 30 to 50% of DFU after 3 months and approximately 50% of venous stasis ulcers. Pressure ulcers are more difficult as they are associated with immobility, malnutrition and tobacco abuse.

In addition to the chronic wound study at Mission Health, Imbed Biosciences has enrolled several other wound care centers and hospitals, and is seeking additional clinical partners to evaluate MicroLyte® Ag Matrix in other approved indications including burns and surgical applications.  A nationwide patient registry will be established to document and assess the real-world use of MicroLyte® Ag Matrix, as well as economic outcome information.

“Imbed is very pleased to have a world-class healthcare system like Mission Health evaluating MicroLyte Ag and assessing how the product can best help its patients with slow-healing and stalled wounds,” said Imbed’s President and CEO, Ankit Agarwal. “The early results seem very promising, so we are eager see the outcome of this study as well as future studies that we are planning with other clinical partners.”

Institutions interested in participating in the clinical research program should email info@imbedbio.com. Additional information about the study at Mission Health can be found at www.clinicaltrials.gov under identifier NCT03204851. Information about MicroLyte Ag can be found at www.MicroLyteAg.com.

About Imbed Biosciences, Inc.

Imbed Biosciences is a privately held medical device company developing next-generation medical devices for the management of burns, chronic ulcers, gastro-intestinal defects, and soft-tissue repair. The company has a portfolio of products in development based on its patented MicroLyte® matrix polymeric multilayer platform that presents bioactive molecules on tissue surfaces to combat local pain and infections, support soft-tissue repair, and reduce antibiotic/opioid abuse. Imbed is backed by venture capital group WISC Partners based in Madison, WI, and has received research grants from the National Institutes of Health and the National Science Foundation. For more information, please visit www.imbedbio.com, www.MicroLyteAg.com, facebook.com/imbedbio, or @MicroLyteAgMtrx on twitter.

MicroLyte® Ag Matrix Added to Formulary at Rush Medical Center

Madison, WI, May 31, 2018 – Imbed Biosciences, a developer of advanced biomaterials and wound care devices, announced today that its flagship product, MicroLyte® Ag Matrix,is now available to physicians and other clinicians at Rush University Medical Center in Chicago, IL.

MicroLyte® Ag Matrix is the first product of its kind to combine antimicrobial silver in a bioresorbable, synthetic matrix that allows tissue growth and does not require removal from the wound bed. Designed to be safer and more readily adherent to the varied topography of complex wound beds where potential sources of infection can sequester themselves, MicroLyte® Ag Matrixworks differently than conventional silver-impregnated wound dressings which server as crude depots of silver.

“Getting on the formulary at Rush University Medical Center is an exciting an important step in continuing to getting MicroLyte® Ag Matrixinto the marketplace where it an be used to improve outcomes for patients,” said Imbed’s President and CEO, Ankit Agarwal. “Through future collaborations at Rush and other leading medical centers we will continue to prove and expand the clinical utility of MicroLyte® Ag Matrix.

About Imbed Biosciences, Inc.

Imbed Biosciences is a privately held medical device company developing next-generation medical devices for the management of burns, chronic ulcers, gastro-intestinal defects, and tissue repair. Company has a portfolio of products in development based on its patented polymeric Microfilm™ platform that present bioactive molecules on tissue surfaces to manage wound infections, biofilms, and local pain and support wound healing. Imbed is backed by venture capital group WISC Partners based in Madison, WI. Company has also received research grants from National Institutes of Health and National Science Foundation. For more information, please visit www.imbedbio.com, www.MicroLyteAg.com, facebook.com/imbedbio, or @imbedbio on twitter.

Imbed Biosciences’ Key Patent Claims Granted in Japan

Madison, WI, April 3, 2018– Today Imbed Biosciences, Inc. announced that the Japan Patent Office has granted 14 claims of the company’s Japanese Patent Application No. 2015-541849, titled “Methods and Compositions for Wound Healing.”

The granted claims provide comprehensive coverage to Imbed’s nanometer-thick polymer multilayer matrix technology, which driven by its nanoscale engineering conforms intimately to the soft tissue, including micro-crevices, of surface wounds or internal organs, and is ultimately bioresorbed. This is a groundbreaking scientific advance that has enabled the realization of the long-held dream of engineering the soft tissue for addressing many healthcare challenges including drug delivery with minimal side effects, preventing surgical site infections, and accelerating the healing of acute and chronic/recalcitrant wounds.

The claims granted cover the nanoscale architecture of polymer multilayer matrix, adjacent polymeric layers and a variety of bioactives—including antimicrobial agents, antibiofilm agents, growth factors, hemostatic agents, peptides, anticoagulant, analgesics, or other drugs—that can be incorporated in the matrix and subsequently delivered to the soft tissue in controlled manner for effective therapeutic action.

Based on this technology, Imbed’s first FDA-cleared product MicroLyte® Ag Matrix is available for over-the-counter and Rx purchase on microlyteag.com. MicroLyte® Ag Matrix not only prevents microbial colonization in fresh wounds but also jumpstarts the healing of persistent chronic wounds that have been non-healing for months and years.

For further information, please contact:

Gaurav Pranami, Ph.D.

Vice President of Research & Development

(608) 237-1526

gpranami@imbedbio.com

About Imbed Biosciences, Inc.

Imbed Biosciences is a privately held medical device company developing next-generation medical devices for the management of burns, chronic ulcers, gastro-intestinal defects, and soft-tissue repair. The company has a portfolio of products in development based on its patented MicroLyte® matrix polymeric multilayer platform that presents bioactive molecules on tissue surfaces to combat local pain and infections, support soft-tissue repair, and reduce antibiotic/opioid abuse. Imbed is backed by venture capital group WISC Partners based in Madison, WI, and has received research grants from the National Institutes of Health and the National Science Foundation. For more information, please visit www.imbedbio.com, www.MicroLyteAg.com, facebook.com/imbedbio, or @MicroLyteAgMtrx on twitter.

Imbed Biosciences Advanced Wound Care Portfolio Highlighted SAWC Spring 2017

Imbed Biosciences Advanced Wound Care Portfolio Highlighted SAWC Spring 2017

Madison, WI, April 4, 2017 – Imbed Biosciences, a developer of advanced biomaterials and wound care devices, announced today that the company will present new data and information featuring its MicroLyte™ antimicrobial and antibiofilm wound dressings at the Spring Symposium on Advanced Wound Care (SAWC) in San Diego, CA from April 5-8, 2017. The company will also have a presence in the exhibitor space at booth #1110. SAWC is the nation’s largest interdisciplinary wound care forum.

The company’s poster presentations will highlight research conducted by multi-disciplinary teams internal to Imbed Biosciences, as well as at the University of Wisconsin-Madison, the University of California-Davis, and Mission Hospital (Asheville, NC) including recent clinical outcomes using the company’s breakthrough MicroLyte™ Ag antimicrobial wound dressing on complex chronic wounds. The study is ongoing and involves 100 patients at Mission Hospital with a variety of complex chronic wounds. Imbed will also present veterinary case study outcomes as well as development of a dressing which can reliably eradicate an established biofilm in a wound bed and thus be used in an infected wound.

“The work that will be presented at SAWC represents a wide range of our current research and commercial activities. Meeting attendees will see clinical outcomes in both human and veterinary patients along with results from our early development work on a next generation antibiofilm product,” said Ankit Agarwal, President and CEO of Imbed Biosciences.

Additionally, prospective users will get a first-look at Imbed’s groundbreaking, FDA-cleared MicroLyte™ Ag ultrathin, antimicrobial wound dressing. MicroLyte™ Ag has only a fraction of the silver of competitive dressings, leading to lower incidences of tissue staining and toxicity while still maintaining high antimicrobial activity. FDA cleared MicroLyte™ Ag for use for up to three days in acute wounds such as, lacerations, skin tears, abrasions, surgical wounds (donor and graft sites, incisions), partial thickness first and second degree burns, and partial to full-thickness dermal ulcers such as, diabetic, decubitus, venous stasis, arterial stasis ulcers.

Poster presentations of interest include:

Ultrathin Hydrogel Dressings Containing Gallium Ions and Silver Nanoparticles for the Elimination of Biofilms
G. Pranami1, T. B. Nelson1, E. C. Crawford1, J. L. Dalsin1, M. H. Herron2, C. J. Czuprunski3, N. L. Abbott2, A. Agarwal1,2
1Imbed Biosciences Inc., Madison, WI, USA; 2Department of Chemical Engineering, University of Wisconsin-Madison; 3School Of Veterinary Medicine, University of Wisconsin-Madison

Use of an antimicrobial microfilm wound dressing in spontaneous wounds in animals
Jonathan F. McAnulty, DVM, PhD1 and Michael J. Schurr, MD2
1Department of Surgical Sciences, University of Wisconsin – Madison, WI; 2Mission Hospital, Asheville, NC

Ultrathin Dissolvable Antimicrobial Wound Dressing Is Safe and Effective In Patients With Complex Chronic Wounds
David Humphrey, MD1, Michael J. Schurr, MD2, William Shillinglaw MD1
1Mission Hospital, Asheville NC; 2MAHEC Department of Surgery, Asheville, NC

About Imbed Biosciences, Inc.

Imbed Biosciences is a privately held medical device company developing next-generation medical devices for the management of burns, chronic ulcers, gastro-intestinal defects, and tissue repair. Company has a portfolio of products in development based on its patented polymeric Microfilm™ platform that present bioactive molecules on tissue surfaces to manage wound infections, biofilms, and local pain and support wound healing. Imbed is backed by venture capital group WISC Partners based in Madison, WI. Company has also received research grants from National Institutes of Health and National Science Foundation. For more information, visit www.imbedbio.com and follow facebook.com/imbedbio and @imbedbio on twitter.

Imbed Bio Recruits Jeffrey Dalsin To Lead Product Development

IMBED BIO RECRUITS JEFFREY DALSIN TO LEAD PRODUCT DEVELOPMENT

Madison, WI, October 1, 2016 – Imbed Biosciences, a developer of advanced biomaterials and wound care devices, announced today that Jeffrey Dalsin, Ph.D. will join the Imbed leadership team as Vice President of Product Development. Dr. Dalsin will lead development of Imbed’s flagship product Microlyte® Ag wound dressings and product pipeline under quality control for new medical applications.  He brings more than 15 years’ experience developing novel biomaterials and medical devices.  Based on his doctoral work, Jeff helped cofound Nerites Corporation, a start-up that commercialized an innovative surgical adhesive and served as Director of Product Development.  In that role, Jeff wore many hats and gained broad start-up operational experience through the company’s successful acquisition in 2011.   Most recently, he led a start-up ultrasound technology company.  Jeff earned a B.S. in Life Sciences from the University of Illinois at Urbana-Champaign and M.S. and Ph.D. degrees from Northwestern University.

“Jeff served as a consultant to Imbed in the company’s early days on SBIR grants and quality management system. He is an excellent scientist and brings rigor of managing product development in start-up environment.  I am happy to welcome him back in a more formal role,” said Ankit Agarwal, Imbed’s President and CEO.

“I’ve known Ankit for several years now and have followed Imbed’s progress with great interest.  I am very happy to have the opportunity to again contribute to this team and assist in bringing a much-need wound care device to clinical users,” said Dalsin.

 

About Imbed Biosciences, Inc.

Imbed Biosciences is a privately held medical device company developing next-generation medical devices for the management of burns, chronic ulcers, gastro-intestinal defects, and tissue repair. Company has a portfolio of products in development based on its patented polymeric Microfilm™ platform that present bioactive molecules on tissue surfaces to manage wound infections, biofilms, and local pain and support wound healing. Imbed is backed by venture capital group WISC Partners based in Madison, WI. Company has also received research grants from National Institutes of Health and National Science Foundation. For more information, visit www.imbedbio.com and follow facebook.com/imbedbio and @imbedbio on twitter.

CONTACT INFORMATION

Ankit Agarwal, CEO, Imbed Biosciences Inc.

ankit@imbedbio.com

Imbed Biosciences Secures ISO 13485:2003 Certification

IMBED BIOSCIENCES SECURES ISO 13485:2003 CERTIFICATION

 

Madison, WI, September 9, 2016 – Imbed Biosciences, a developer of advanced biomaterials and wound care devices, announced today that the company has received certification from British Standards Institution (BSI) Group America, Inc. that the company complies with the requirements of ISO 13485:2003 for an integrated Quality Management System across all functions of the business, from design and development to manufacturing and supply. The scope of the certificate includes the design, manufacture, and distribution of sterile wound dressings with medicinal substances.

“This is a crucially important step in bringing our first antimicrobial wound dressing product, MicroLyte AG, to global marketplace,” said Imbed’s President and CEO Ankit Agarwal.  “Furthermore, I am very pleased that our small team has been able to achieve this certification in a relatively short period of time in a very capital efficient manner.  ISO 13485 certification provides an important level of assurance to our customers and partners that Imbed can reliably provide high quality products.

About Imbed Biosciences, Inc.

Imbed Biosciences is a privately held medical device company developing next-generation medical devices for the management of burns, chronic ulcers, gastro-intestinal defects, and tissue repair. Company has a portfolio of products in development based on its patented polymeric Microfilm™ platform that present bioactive molecules on tissue surfaces to manage wound infections, biofilms, and local pain and support wound healing. Imbed is backed by venture capital group WISC Partners based in Madison, WI. Company has also received research grants from National Institutes of Health and National Science Foundation. For more information, visit www.imbedbio.com and follow facebook.com/imbedbio and @imbedbio on twitter.

CONTACT INFORMATION

Ankit Agarwal, CEO, Imbed Biosciences Inc.

ankit@imbedbio.com

pdf-icon1